Doubling up against prostate

Even before seeing the final efficacy results from an ongoing Phase II trial of its autologous vaccine against prostate specific antigen (PSA), Immuno-Designed Molecules S.A. has closed a deal to combine the vaccine with an antibody in development at Medarex Inc. The hope

Read the full 432 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE